Antibody-drug conjugates (ADCs) represent a therapeutic class of agents designed to selectively deliver cytotoxic payloads to cancer cells. With the increasingly positioning of ADCs in the clinical practice, combinations with other treatment modalities, including radiation therapy (RT), will open new opportunities but also challenges. This review evaluates ADC-RT interactions, examining therapeutic synergies and potential caveats. ADC payloads can be radiosensitizing, enhancing cytotoxicity when used in combination with RT. Antigens targeted by ADCs can have various tissue expressions, resulting in possible off-target toxicities by tissue radiosensitization. Notably, the HER-2-directed ADC trastuzumab emtansine has appeared to increase the risk of radionecrosis when used concomitantly with brain RT, as glial cells can express HER2, too. Other possible organ-specific effects are discussed, such as pulmonary and cardiac toxicities. The lack of robust clinical data on the ADC-RT combination raises concerns regarding specific side effects and the ultimate trade-off of toxicity and safety of some combined approaches. Clinical studies are needed to assess ADC-RT combination safety and efficacy.
Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates / S. Natangelo, D. Trapani, C. Koukoutzeli, L. Boscolo Bielo, G. Marvaso, B.A. Jereczek-Fossa, G. Curigliano. - In: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. - ISSN 1879-0461. - 195:(2024 Jan 24), pp. 104270.1-104270.15. [10.1016/j.critrevonc.2024.104270]
Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates
S. NatangeloPrimo
;D. TrapaniSecondo
Conceptualization
;L. Boscolo Bielo;G. Marvaso;B.A. Jereczek-FossaPenultimo
;G. Curigliano
Ultimo
2024
Abstract
Antibody-drug conjugates (ADCs) represent a therapeutic class of agents designed to selectively deliver cytotoxic payloads to cancer cells. With the increasingly positioning of ADCs in the clinical practice, combinations with other treatment modalities, including radiation therapy (RT), will open new opportunities but also challenges. This review evaluates ADC-RT interactions, examining therapeutic synergies and potential caveats. ADC payloads can be radiosensitizing, enhancing cytotoxicity when used in combination with RT. Antigens targeted by ADCs can have various tissue expressions, resulting in possible off-target toxicities by tissue radiosensitization. Notably, the HER-2-directed ADC trastuzumab emtansine has appeared to increase the risk of radionecrosis when used concomitantly with brain RT, as glial cells can express HER2, too. Other possible organ-specific effects are discussed, such as pulmonary and cardiac toxicities. The lack of robust clinical data on the ADC-RT combination raises concerns regarding specific side effects and the ultimate trade-off of toxicity and safety of some combined approaches. Clinical studies are needed to assess ADC-RT combination safety and efficacy.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S1040842824000131-main.pdf
accesso riservato
Descrizione: Articolo
Tipologia:
Publisher's version/PDF
Dimensione
3.9 MB
Formato
Adobe PDF
|
3.9 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.